Jessica Hergert


Single-agent and combo immunotherapy as second-line treatment of gynecologic cancers

October 05, 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.